Quantinno Capital Management LP Buys 1,126 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantinno Capital Management LP boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 50.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,366 shares of the biopharmaceutical company’s stock after purchasing an additional 1,126 shares during the quarter. Quantinno Capital Management LP’s holdings in Alnylam Pharmaceuticals were worth $926,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth $7,009,000. Ikarian Capital LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $2,404,000. Investment Management Corp of Ontario lifted its holdings in Alnylam Pharmaceuticals by 153.5% during the third quarter. Investment Management Corp of Ontario now owns 7,059 shares of the biopharmaceutical company’s stock worth $1,941,000 after acquiring an additional 4,274 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at about $4,539,000. Finally, True Wealth Design LLC grew its stake in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock valued at $2,540,455 in the last quarter. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of ALNY stock opened at $245.44 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The stock has a market cap of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32. The firm’s 50-day moving average is $267.01 and its 200-day moving average is $248.16. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter last year, the company earned $1.15 EPS. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Piper Sandler restated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.